ELTP · All filings · Read this filing

What changed 10-K

Item 3. Legal Proceedings

2025-06-30 compared with 2024-07-01 · 6 added, 4 removed, 13 unchanged (43% of the section changed)

3 unchanged sentences

14, 2023, a patent infringement suit was filed in the District Court of New Jersey by Purdue Pharma.

Elite obtained agreement with Purdue

to stay the litigation for six months.

Elite’s launch of a generic Oxycontin will depend on approval by the FDA and the outcome

of various litigations involving Purdue or the expiry of the patents listed on the Orange Book.

The parties submitted several stipulations

and proposed orders for staying the case until March 19, 2025 where the parties submitted a stipulation and order lifting the existing

stipulated stay.

On April 18, 2025 Purdue filed an amended complaint.

Elite’s launch of a generic Oxycontin will depend on approval

by the FDA and the outcome of various litigation involving Purdue or the expiry of the patents listed on the Orange Book.

the ordinary course of business, we may be subject to litigation from time to time.

8 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.